LAVA Therapeutics (NASDAQ:LVTX) Receives Neutral Rating from HC Wainwright

LAVA Therapeutics (NASDAQ:LVTX)‘s stock had its “neutral” rating reaffirmed by research analysts at HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They currently have a $1.50 target price on the stock, down from their previous target price of $2.00. HC Wainwright’s target price would suggest a potential upside of 11.11% from the stock’s current price.

A number of other brokerages have also recently issued reports on LVTX. Leerink Partners reiterated a “market perform” rating and issued a $2.00 target price (down from $11.00) on shares of LAVA Therapeutics in a report on Thursday, December 12th. JMP Securities reaffirmed a “market perform” rating and set a $6.00 price objective on shares of LAVA Therapeutics in a report on Wednesday, December 11th. Citizens Jmp downgraded LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, December 11th. Finally, Leerink Partnrs lowered shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 12th. Five research analysts have rated the stock with a hold rating, Based on data from MarketBeat, LAVA Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $3.17.

LAVA Therapeutics Trading Up 0.7 %

Shares of NASDAQ LVTX opened at $1.35 on Thursday. LAVA Therapeutics has a 12 month low of $0.85 and a 12 month high of $6.47. The company has a market capitalization of $35.49 million, a P/E ratio of -1.31 and a beta of 0.57. The stock has a 50 day moving average of $0.99 and a 200-day moving average of $1.44.

LAVA Therapeutics (NASDAQ:LVTX) last issued its earnings results on Tuesday, December 10th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.11). Analysts predict that LAVA Therapeutics will post -1.13 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in LVTX. Virtu Financial LLC bought a new stake in LAVA Therapeutics during the 3rd quarter valued at about $32,000. BNP Paribas Financial Markets acquired a new stake in shares of LAVA Therapeutics during the 4th quarter valued at about $40,000. Finally, Sanofi purchased a new position in shares of LAVA Therapeutics in the fourth quarter valued at approximately $1,825,000.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.